Skip to content
Take Aurally Therapeutics: COPD episode artwork

Dec 22, 2017 35 min

Take Aurally Therapeutics: COPD

from Take Aurally Hosted by Take Aurally

In this second episode in our new Therapeutics section ED Pharmacist Kunal Gohil came down to DREEAM to talk us through the treatment of COPD. Check out www.takeaurally.com for more information. Take Aurally can also be found on both Facebook and Twitter as can NUH DREEAM.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Take Aurally Therapeutics: COPD

0:00 35:10
of matches

Transcript Auto-generated, may contain errors

Thanks for downloading and welcome to Take Orally, the emergency medicine podcast recorded at Dream Queen's Medical Centre at Nottingham. In this episode we'll be discussing treatment of COPD. As everyone information is correct at the time of recording, all guidelines mentioned are correct for Nottingham University Hospital's NHS Trust. Other trust guidelines may vary. All views and opinions are the speaker's own.

Hello, welcome back to Nick Orling. Jamie Thomas here, teacher fellow in medicine. Once again, ED pharmacist, Canal Gahill is here. Good to be here again. Welcome back, Canal. Thank you for coming to join us. You previously come to talk to us about treatment of hypertension. In this episode, we're going to be looking at COPD, chronic obstructive pulmonary disease. We're not so much looking at the emergency treatment of COPD, we're looking at the initiation of treatment on patients who've just been diagnosed with COPD. So again, it's a primary care setting.

Or medics picking this up maybe on the ward. At this point, I draw your attention to the previous Take Orly podcast on COPD with myself and Charlie Peel, where we go through the emergency management of COPD, discussing nebulisers, intravenous steroids and non-invasive ventilation. So please go to there for more on that and more on the diagnosis of COPD in that podcast as well. Right then, so the guidelines we're looking at here, you have our very own Trust Guidelines in front of you as well, and I've got the NICE Guidelines CG101. which I think our guidelines are very much based on these guidelines. Yeah, it's pretty much there, yeah. So very much talking about the diagnosis of COPD. And I think front and centre in here, before we're even doing anything else, stop smoking. Stop smoking, absolutely. If there's one intervention before you even try and pick up your pen to prescribe anything for your patient with potential COPD is to stop smoking. In terms of, there's some evidence that we've got locally saying...

just putting that as an intervention is the most cost effective and getting the most amount of benefit long term for these patients. So as soon as you dig COPD, we should be thinking about NRT and encouraging your patients to stop smoking. And it's always a difficult conversation. Patients could have been smoking for absolute yonks, which is potentially the reason they've got COPD. So putting a lot of effort into that initial phase of trying to get them to stop smoking is going to do a lot more good than starting to use very clever inhalers and clever therapies down the line. So I think the key point to start with your COPD patient is to think about...

stopping smoking, get a good, effective way that works for that patient off the fags and starting to reduce their smoking amounts and then hopefully get them off it altogether. There's a lot of evidence about a year down the line, five years down the line, ten years down the line, they can regain some of their pulmonary function and their risk of deterioration goes down massively. So I've got some evidence here. guidance that was made by the London respiratory team where they looked at qualies gained, and stopping smoking, even potentially with pharmacotherapy or not pharmacotherapy, costs about £2,000 of qualies, which is, if you know anything about qualies, that's very cheap for a quali in that patient profile. And when you're going up to very clever interventions, you could end up spending £20,000 to £30,000 per quali on these things. So it's a no-brainer, it's trying your best to get them to stop smoking. I think so.

Yes, they've damaged their lungs, but it's not just thinking, you know, you've damaged your lungs, you may as well carry on smoking. No, stop, you will get some benefit. Yeah, it's in the psychology of patients, unfortunately. When you talk to patients like this, they do feel like they've got the diagnosis, and they're often quite actually quite guilty about it. And they don't see the benefit of stopping at that point. It's kind of like, well, I've got it now, so I might as well continue. It's getting that mindset out and educating the patients about the benefit that they can still be. And that's putting the cancer risk to one side as well. Absolutely, yeah. Right then, so our patients have stopped smoking. Excellent. They've been good, but they're still getting breathless quite a lot, and it's affecting their day-to-day activity. Sure. So, nice guidelines mentioned as their first line to introduce inhale therapy.

a short-acting beta 2 agonist or a short-acting muscularinic antagonist. That's right, yeah. So NICE doesn't necessarily differentiate between which one you want to use. There's some local guidelines about which one you might want to use and the side effect profile for the patients. So these two drugs, we'll start with the SABAs, as we call them, so the short-acting beta 2 agonist. So this is a symptomimetic agent inhaled, so it's going to act by agonising beta receptions in the lung.

And as a result, you're going to get bronchodilation. So idea being that they can get more puff into their lungs with that. Salbutamol is the first choice agent we usually use, which has been around for yorks. Ventolin is the brand name. And this is a quick-acting inhaler that you can use whenever needed, effectively, for periods of breathlessness. And we can even advise patients to use it with COPD before they're going to expose themselves to situations where they might get an exacerbation. So if they're trying to go to the gym, go for a long walk, going even into a dusty environment or something like that, we can encourage them to...

take it beforehand to preempt it and also to relieve it. The other short-acting beta agonist is a drug called terbutylin. Brickanil is the brand name. Again, very similar to salbutyl in how it works. Slightly different preparation. So it's a dry powder inhaler rather than a metered dose inhaler, which we'll talk a little bit about in a little while about the inhaler devices. Either are an option, and it's very much sort of giving the patient the option to give them a device that they can use most easily and they feel most comfortable with. Now, if we talk a bit about the short-acting...

B2-2 agonists. Obviously bronchidylation is what we're going for. Unfortunately, they're not perfectly discriminatory for the respiratory tract, so there'll be some level of absorption into the bloodstream through the lung. And as a result, there are potentially some cardiac side effects that you have to warn patients to look out for, and potentially some peripheral ones as well. So a classic side effect of using a sarbutamol inhaler would be potentially a tachycardia. It makes the heart race because it is a sympathomimetic, so it's going to potentially increase sympathetic drive. Equally, you can potentially get some...

action into the periphery, so a fine tremor is also quite common with salbutamal use. Now, neither of these would be reasons to stop using the inhaler. The benefit of using it to open up the lungs far outweighs the staccardia or the peripheral tremor. If we're starting to use these drugs in patients that are predisposed to arrhythmias or diagnosed with arrhythmias or where the tremor is getting so bad that it's affecting day-to-day function, then we should be thinking about maybe reviewing it and using something else. They're the key side effects. There's no specific contraindications for using these inhalers because the benefit is so high usually. And it's not necessarily something they're using constantly. And obviously the more they use it, the more the side effects will come out effectively. So we talked a bit of the, those are the beta-2 agonists. We mentioned the short-acting anti-muscarinics. So SAMRs. SAMRs, yeah, SAMRs, as we know them as. So there's only one drug that we use at the moment for that, which is a drug called ipratropium. The brand name is called Atrovent, which is a metered dose inhaler. It's got a similar mechanism of action in terms of what we're trying to do.

of how it works in the lung. Antimuscarinic action will work on the smooth muscle in the lung, and it will cause relaxation in the smooth muscle, and thus you'll get some bronchodilation. There is one little additional benefit, which is why some clinicians will prefer to offer it first-line, which is being an antimuscarinic, it will tend to dry you up. So a classic side effect of the atropines and all the antimuscarin agents is you'll get a decrease in secretions, so classically saliva, but in the lung we're going to get potentially some mucous suppression. which your COPD patient who might have a bronchitis or quite thick mucus, because they quite classically will have a chronic cough, drying that up will actually give them some extra symptom benefit. There is a toss-up for that because also they might get some oropharyngeal sort of in there. They might get a bit of dry mouth. It can sometimes give you slightly higher risk of getting oral brush and things like this. And some patients don't like that, which can be a toss-up. But it is another option to be able to consider two puffs up to four times a day.

And those can be used together? You can. To be honest, I haven't seen too many patients that use both. I have seen patients have access to both of them. So you might find that your COPD patient would prefer to use a SAMR when they've got more of a cough that's productive because it helps with that mucous secretion, whereas when they're outside and they feel more of a breathless situation, they might prefer a salbutal inhaler or something like that. There's no reason you couldn't use them together. You would worry that you haven't optimized them for either one if they're having to use them together regularly. So those would be the two short-acting...

agents that they can use as and when they need okay so those are our short acting what's about our longer acting so longer acting so yeah we then move on to the what we call the labbers and the lammers so in terms of their mechanism of action identical to what we just said about how they work in terms of their bronchodilation we start off with the labbers so the two classic ones, there's a multitude of new inhalers and new novel drugs that are coming out, and I won't try and talk about all of them, but the two classic ones that most patients are on are Salmeterol, which is one of the constituent ingredients in Ceratide, which is one of the combination products that's quite well known, or the other one being Formorterol, which is one of the constituent products in Simpacol, which is another quite classic one, usually twice a day.

So they've got, they will sit in, the way the chemical structure is versus salbutamol, they've got a very long side chain, which means they sit in pulmonary tissue and they sit on that receptor and bronchodilate for a longer period of time. So usually it's one or two puffs of that twice a day. You have to be a little bit careful in terms of combination inhalers because these are classically in combinations, but you can get them as monotherapy for initials. So once we're putting patients onto a new step or increasing them, we're trying to get them one inhaler wherever possible. which helps them in terms of compliance. There's some evidence to say that it's better for compliance. There's a couple of new novel ones, things like olodaterol and a couple of other new labbers that are coming out, but we won't talk too much about them. They've got a very similar clinical profile. Shall we talk about when we go to the lab? Yeah, shall we talk about that? Let's do that, and then we can come on to the other draft. So, effectively, we're looking at... So, yeah, so NICE criteria mentioned that...

Basically, it's all about their FEV1. So if you've got a patient who is taking the short-acting inhalers, is remaining breathless, getting frequent exacerbations, you think about them moving on to the longer treatment. So you measure their FEV1. And if it is equal to or greater than 50% of the predicted, you're going to start a LABA or a LAMA. That's right. If their FEV1 is less than 50%, you will start a LABA with an inhaled corticosteroid in a combination inhaler or a LAMA. So it's looking at...

Are they still breathless on the initial treatment? Are they still getting frequent exacerbations, measuring their FEV1? Yeah, so this is very much about breathlessness rather than, say, exacerbations. This is sort of the normal day-to-day functioning. And it makes logical sense, doesn't it? If somebody's having to use their short acting very often, why not give them a long acting? It's going to help them out in the long run. So we talked about the labbers.

the salmitrol and the formortrol. The LAMAs are the ones that are kind of the new kids on the block to a certain extent. They're the newest of the novel therapies. The one most people will be familiar with is something called tyotropium, Spiriva, which is a clever little device where you put a capsule in and you crush it. It's actually quite an old-fashioned product, but people quite like it. It's a once-a-day preparation, which, again, is really useful, which is actually a reason that quite often they're these days preferred over the Lava as your first intervention for a long-acting product. So tyotropium is quite high up the list of what will start as an initial therapy. Do have to mention, though, obviously,

It is an anti-moscarinic, and you are going to get some absorption, like we said with the salbutamol beforehand. So even though it's not particularly contraindicated in anything, I think if you've got very bad renal function, you have to be careful using it because it can accumulate. But if you've got effects, things like glaucoma, where you can't tolerate anti-moscarinics, you have to be careful in starting this. Also, it's important to note, we will not routinely give people a llama and a sama together. So we said before about sama, the protropium being an option. If you put somebody on a llama, it negates the need for a...

because you are literally hitting the same receptor. So if you give somebody tyotropium and then they start using it butropium on top of that for exacerbations, it's going to be very ineffective because you've already done that. So at that point, you're using two different drugs. So once you've got them on the mamma, they should probably be using a Saba to supplement that if they need it. Okay, so we've looked there really at our beta-2 agonist, we've looked at antinosaurinics.

Nice, we just sort of mentioned they're talking about steroids as well. So shall we sort of move on to other drugs that we can use now? Absolutely, yeah. So the last sort of main inhaled therapy that you're going to throw on top of this. So obviously the Lama and the Lama are your first.

longer-term intervention, and then you'll be considering an inhaled steroid if there's frequent exacerbations, I think is the quite classic reason. So when we're talking about steroids, generally speaking, we don't use inhaled steroids on the road. They become a combination product. So you wouldn't usually see a COPD patient on a monotherapy with an inhaled corticosteroid. It should be in combination with a LABA or a LAMA at that point, usually a LABA. So the classic products we have for that are, there's serotide, which is probably the...

most well-known product, which is a combination of a lava salmitrol with a corticosteroid fluticosone. There's a couple of different agents as well, so there's simpacort budesonide with formal troll, and the other one that we use quite a lot of is simpacort fossaire, which is bethazone and formal troll. So once you're using steroids, the idea is to prevent exacerbations coming in future. And there is a little bit of evidence about saying that it can reduce that. But there is also a bit of evidence to say that long-term use of these inhaled steroids can start causing problems with pneumonias. And that's why we have to review the therapy long-term if they're getting lots and lots of pneumonias whilst on corticosteroids. Because you're immunosuppressing the truth. Exactly, exactly. Key thing with these products is, again, consider highly the patient choice about the device. That's going to mainly govern which product you're going to pick.

And introducing a steroid, some of these preparations can have quite potent amounts of inhaled steroid in them. And again, we've said before, we can have some absorption systemically from the lung. So you're going to potentially give a lot of steroid to these people, a significant amount. So you have to consider the long-term effects of steroids, withdrawing abruptly, even sometimes thinking long-term about calcium supplementation and things like that. The classic thing that will counsel for steroids would be steroid deposition in the mouth and the throat is going to increase your risk of having oral brush. So when people are using these products, we would tell them to rinse their mouth out with a mouthwash or even a little bit of water, which will reduce that risk massively.

Important to note with the steroids is, because of the way the preparations are, steroids are not always equivalent. So an example would be a clenial inhaler, which is a beclomethazone inhaler. You wouldn't necessarily use that in COPD. Now, there's beclomethazone in Foster, which is its steroid, but it's not dose equivalent with the clenium. The particles are smaller, so you get a more potent effect. So when you're considering how much of your dose to prescribe, make sure you're considering that per the brand and particle size that you're using. Various other newer products coming out into the arena. There's things like Relvar, Noro, and things like this.

We won't talk about too much because there's so many different types of inhalation. We can't get through all of them. But it's very much on that patient choice. Sure. And assessing inhaler technique the whole time, I imagine. Making sure our patients, show me how you take it. Yeah. I mean, inhaler technique is the single... As a pharmacist, this is very much... My area is teaching patients how to use their inhalers. So inhalers, unfortunately, aren't ideal in terms of patients don't generally use them very well. That's why there's so many different types. So when you do prescribe the inhaler, it's incredibly important to teach them how to use it and make sure they're happy and able to use it. So we'll talk a bit about inhalers.

There's four main types altogether. This is how I group them. So there's one called the metered dose inhaler, which is your sort of one that you press down on and it puffs out a cloud. Your classic Ventolin inhaler. Probably the most prevalent type of inhaler that we have and probably the most difficult to use out of all of them. There's a high velocity coming out of that inhaler and you have to coordinate reading very, very carefully to be able to get that dose into your lung. It's actually an incredibly difficult thing to do. But the doctors, pharmacists, nurses are not very good at doing it themselves, let alone being able to counsel on it.

They're a good choice in your patient that doesn't have very good respiratory effort. So in terms of not able to take a quick, sharp breath, somebody that breathes quite gently, they're a good choice because the velocity of the particles comes out of the inhaler. You don't have to make that yourself. So the classic thing with these is slow and steady intake of breath. So when people are taking these inhalers, they need to breathe all the way out before they take it. And then when the inhaler's going off, they need to inhale very slowly and very steadily to be able to get proper deposition into the lung.

we can increase the efficiency of these inhalers massively by prescribing a spacer with them. So there's a lot of evidence to say that using these with spacers gets better outcomes. Patients are better at doing. Not all patients enjoy using a spacer because they're a bit big and cumbersome, but we've got some good spacers now that are nice and compact that we can use, and that gives you a barrier which slows the velocity of the inhaled particles coming out and stops it from hitting the back of the throat and lets you inhale it more easily. So that's your classic type of inhaler, your point and push inhaler. The other type of inhaler, main type of inhaler, is what we call a dry powder inhaler.

So this is literally, there's no propellant in the inhaler itself, it relies on the patient, their inhaling effort to be able to get the drug into the lung. Your classic example of this would be something like a Symbacort inhaler, a Turbohaler, or a Ceratide Accuhaler, which is sort of a flying saucer looking one. So those ones, once they're primed properly, and there's various different ways to prime them. some of them can be a twist, some of them can actually unit dose, is that they have to take quite a quick, sharp, big inspiratory effort to be able to break up that dry powder and get it appropriately into the lung. Probably slightly higher risk of also depositing in the mouth in terms of steroids, so you have to be a bit careful getting them to rinse out. So they're quite good for your younger patient who's got good respiratory effort. Generally they don't tend to be as good for patients that they can't draw that short, sharp breath.

So that's your two classic types of inhalers. The new two subtypes that have come out is the older-fashioned single-capsule inhaler, which is a type of dry-powder inhaler. So that's like your Spiriva, the diatropium. It would be literally a capsule that looks like a capsule you'd swallow, which can be a big problem because I've had plenty of patients that have been prescribed Spiriva and are taking them orally when they should be putting them into a device. Yeah, we can laugh, but it's really important because they weren't told and they don't know. And it looks like a capsule you swallow, so they can be forgiven.

So the capsule is literally put into a device, a hand inhaler. There's a button to snap that capsule to bring the powder out, and then they need that short, sharp, powerful drawing of breath to be able to get it into the lung. This can be a bit fiddly for your older patients, so think about your patients with osteoarthritis, things where they can't manipulate small things. They might not be a very good option in that patient class. A few other examples of those capsule-type inhalers as well, but the plastic's being superior about the Spareba. The last one being what we call a Respimat inhaler, which you don't see as much of, but it's actually quite a clever type of inhaler.

That is an inhaler that causes a fine mist of particles, really slow-moving fine mist. And the classic one is Spiriva Residumab. The idea of that being that it's really slow-moving, it's very easy to slowly and steadily inhale it in. They can be quite tricky to use in terms of they've got a clicking mechanism and a releasing mechanism. And so if we are using that with patients, we've got to make sure that they're absolutely comfortable using it and they know how to inhale it. You don't see too many of those generally, but it is an option for people that, again, have that inspiratory effort. Nice.

mentions about oral corticosteroids basically saying maintenance not usually recommended basically for risks of adrenal suppression osteoporosis so if there is a maintenance dose want to keep it as low as possible I know a lot of patients do have a rescue dose of steroids if they feel an effective exacerbation like they'll have a rescue dose of an antiviral to take and patients may be discharged for the short course of but maintenance dose not really recommended and then it moves on to mentioning a word which is always fun to say theophylline oral theophylline only to be used if the trial of SABRS and LABRS has not really worked, or if the patient is unable to use inhaled therapy. Yeah, I mean, when we're getting into the offlin territory, so when we talk about the offlin, it's what we call a phosphodiesterase inhibitor, a zampine derivative. It's got a very, very complicated mechanism of action, but for all intents and purposes, it is a bronchodilator, an oral bronchodilator. It's not a very pleasant drug to use because it's got a very narrow therapeutic index, and because of that narrow therapeutic index...

It's got a very small window of dosing where you've got efficacy. So if you're below that, it's not going to be very effective. If you're above that, you're going to get toxic symptoms, and it can potentially be quite toxic. When you're starting to start theophylline with these patients, you're getting to the stage where they're becoming quite refractory for all treatments. They potentially need levels doing periodically after they take it. One of the real problems with theophylline is that it actually interacts with tobacco, which is quite an interesting one. So your patient that smokes, potentially a COPD patient, might be a slightly higher risk of smoking.

Smoking actually reduces the ophelin levels of blood via a very complicated metabolic mechanism. Now, the problem is that that can vary from day to day. So a patient one day might smoke 20 and the next day not feel like smoking at all. It can actually mean their theophylline levels in their plasma go for a rollercoaster ride and perish, unfortunately, the biggest problem, which is not a problem per se, that if your patient stops smoking and is maintained on the same dose of the ophelin, because that's not suppressing the levels, they'll end up going toxic. So there's a lot of very careful things to be looked at with that.

theophylline and the other drug is aminophylline which is a salt of theophylline as well. It's only really usually going to be recommended by specialists at that point because it's when you're very refractory to inhale therapies. If you are dealing with it just be very careful with its toxic effects and monitoring in terms of levels and that sort of thing. And so another class of drugs that we sort of gloss over a little bit here are the mucolytics as well. So you already mentioned about the anti-muscarinics having a suppressive effect on mucus. Yes, that's right. But these may be for further patients who are, you know, having a chronic cough. Yeah. So you will get some effect on this mucus production in the lung if they're on a LAMA, which should sort of be your first slide intervention. But this is very much a symptomatic kind of treatment. So the drug we use is something called carbocysteine, which is what we call a mucolytic. So it's going to thin out and break up some of that mucus.

COPD patients, as we say, the Blue Lotus who have bronchitis, kind of heavy mucus production, symptomatically they can find that taking this carbocysteine improves their function a little bit. The evidence isn't sort of brilliant for it, from my understanding, but from a risk-benefit point of view, it's a well-tolerated drug. It's got a very small side effect profile, and so it is something, again, we can throw in later on. Another potential thing that's along the same lines is when we start using nebules, saline nebules, which are irritant to the respiratory tract. that would encourage a cough. So that's something, again, a later term intervention in COPD patients where they've got home nebs, for example. They might use saline nebs if they're very congested in their chest and they need to bring some of that stuff up. And it does potentially have some fitting properties as well. And like we've already mentioned, so we've already talked about patients may have rescue antibiotics, they may have rescue steroids.

Moving on, I suppose, we won't cover that here, but just to mention, as you've already mentioned, patients still struggling, this is where nebulisers, home oxygen comes into it as well. Specialist nurse input, specialist hospital consultant input as well at that point. At that sort of point, when you're on the home nebs and the home oxygen, it's very important to remember that COPD, when it's getting to that, is a palliative condition. It's not a condition that at that point is going to get any better. It revolves around symptom management. So there's various things that we can do later on. The rescue antibiotics and the rescue steroids.

There's good evidence for them. The evidence is about stopping patients coming in from hospital unnecessarily. Unfortunately, as we know in hospital, we've got lots of potentially nasty pathogens. Patients don't do well in hospital. And if we can keep COPD patients out of hospital, that is always the best thing to do. They can end up picking up bugs in their lungs that become quite difficult to treat. One of the options, as we say, is the rescue antibiotics. These patients know very, very early on, if they've had the disease for a while, when they're getting an act of sedation. And it gives them the control to be able to treat themselves. And that's usually when we start that process of self-starting antibiotics and steroids.

They need to be very well educated to what the symptoms are to start there. The other thing would be that there's various other potential treatments, so we can put people on prophylactic antibiotics. So azithromycin is a drug that there's some evidence for. We could prescribe that up to three times a week, and it has both an antibiotic sort of prophylaxis effect, as well as having a potential anti-inflammatory effect on the lung as well. So you might find some patients taking regular azithromycin for prevention as well. But at that point, that's quite down the line.

And I also mentioned here in ICE not to give antitussips. So if you have a patient with a stable COPD, don't give them anything that's going to suppress a cough. So this should be clearing. Absolutely. I mean, it's a no-brainer, isn't it? I mean, you do occasionally see it. And it's actually a really important thing as a pharmacist, actually, because we get a lot of potential patients that with COPD and they come up to the counter asking for cough syrup. And it's about education to say you really don't want to stop your cough reflex. It's going to make you worse. Short term, it might stop your cough because these patients tend to cough a lot. But in the long term, antitussips are a real problem. So we should always try and avoid them in COPD.

Brilliant. Any further information, Canal, or have we remastered COPD? It's a very difficult one because, as I say, there is a lot of different products and a lot of different potential routes of treatment for these patients. So this is why we've purposely not specifically gone into every single product and every single inhaler type and how you treat patients. The take-home message, I think, from this is once you've got a formal diagnosis of COPD, that lack of reversibility in the disease...

Do the simple things right first. Get them to stop smoking. And the other thing we didn't touch on, actually, was get the immunisations done. I was about to say, yeah. Flu vaccines, pneumococcal vaccines, things that are going to prevent them from getting problems with their chest because they're going to be at a higher risk of hospitalisations and mortality because of that. Do the simple things well. And when you're starting to look at pharmacological interventions with inhaled therapies, make sure you give the patients something they can use and they understand how to use it. Make that be your key decision in what you're going to prescribe. So you might think that this patient will benefit from a lab and their therapeutic profile will be...

excellent for that, but you might find they just can't use the inhaler and they don't like it and they're getting on really well with the Lama instead. Make that be your key intervention. The devices often have got about three or four different formulations, so for example Simbacort and Foster, they come in a meter dose inhaler, they come in a dry powder inhaler, various different strengths, so give them the product that they can use the best, educate them on how to use it and make sure I think it's managed expectations of what they want. in terms of their disease? Do they want to not go into hospital? Do they want to cure themselves of this disease? You have to be very clear with them and certainly understand what to expect really. But yeah, I think the key thing is simple interventions first and then govern your therapy patient specifically. Yeah, so I mean, we didn't touch on pulmonary rehab, but that's something else that can be used. Yeah, non-pharmacological interventions. So yes, I mean, stop smoking. There are non-pharmacological interventions like pulmonary rehab, the interventions that we've talked about, the vaccinations as well, as you mentioned.

noticing when these things aren't working and escalating appropriately. Absolutely, absolutely. Thank you very much, Kunal. That was the Take Orly Treatment of COPD podcast. For more information, don't forget to check out www.takeorly.com. You can also find Take Orly on both Facebook and Twitter. For more information about research and education opportunities in emergency medicine, acute medicine and major trauma, you can find NUH Dream on both Facebook and Twitter.

Frequently asked questions

How long is this episode of Take Aurally?

This episode is 35 minutes long.

When was this Take Aurally episode published?

This episode was published on December 22, 2017.

Is there a transcript available for this episode?

Yes, a full transcript is available for this episode. You can read the complete transcript on the episode page.

Can I download this Take Aurally episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.